{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003038","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.008254+00:00","generated_at":"2026-05-16T10:38:37.996908+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Milestone closes $75M royalty sale to RTW for etripamil US net sales","bullets":["Closed sale of royalty interest under Royalty Purchase Agreement with RTW Royalty I DAC.","Received $75 million purchase price from funds managed by RTW.","Royalty interest is on annual net product sales of etripamil in the United States.","Previously disclosed on March 27, 2023; FDA approval of etripamil a condition."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003038","json":"https://secwatch.observer/filing/0001104659-26-003038.json","markdown":"https://secwatch.observer/filing/0001104659-26-003038.md","text":"https://secwatch.observer/filing/0001104659-26-003038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926003038/0001104659-26-003038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926003038/tm262948d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:38:37.996908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}